Mar 08 2024 This Week in Cardiology Mar 08 2024 This Week in Cardiology
Plastics and heart disease, the MINT trial letters-to-the-editor and Bayes theorem, and Brugada syndrome are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 9, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Wegovy Is Good for More Than Just Weight Loss
The obesity drug Wegovy can now claim to lower the risk of heart attack, stroke, and other cardiovascular issues in people who are overweight or who have obesity, and also have cardiovascular disease. It’s the first weight-loss drug to carry an indication for heart benefits.
The U.S. Food and Drug Administration (FDA) approved the addition to the label on March 8 based on a study from Wegovy’s manufacturer, Novo Nordisk, showing that the drug lowered the risk of heart attack, stroke, or dying of heart-related issues in this population by 20% compared to people receiving placebo.
[time-brightcove not-tgx=...
Source: TIME: Health - March 8, 2024 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
FDA approves Wegovy weight-loss shot for heart disease patients - including those who are not obese
The FDA approved the medication for this use in non-diabetic patients who had heart disease today, following clinical trials showing it slashed the risk of the complications by up to 28 percent. (Source: the Mail online | Health)
Source: the Mail online | Health - March 8, 2024 Category: Consumer Health News Source Type: news
Wegovy Approved for Major Heart Disease Prevention
(MedPage Today) -- The FDA approved semaglutide (Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight, the agency announced on Friday.
A GLP-1 receptor... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 8, 2024 Category: Cardiology Source Type: news
Shattering the Silence: Paving the path for cardiovascular wellness and diabetes care through the lens of Indian women
Dr. Sarita Rao, Dr. Shehla Shaikh, and Dr. Anupama Dubey dive into the spectrum of heart health and diabetes in the latest drop of the USV health awareness multimedia series—‘Winning the Battle Against Diabetes and Heart Disease in Women—in collaboration with The Economic Times. Together, they unravel and demystify various facets of cardiovascular health and diabetes in women, from subtle signs to potentially high-risk factors and the correlation of stress, hormonal imbalance, and bone health, while mapping the route to seek medical interventions at the right time. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 8, 2024 Category: Pharmaceuticals Source Type: news
D.C. startup lands $8M to improve health care for heart disease patients
The company intends to beef up its team, develop its technology, break into new markets and grow its footprint. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 7, 2024 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
Study Links Tiny Bits of Plastic to Worse Heart Health
We breathe, eat, and drink tiny particles of plastic. But are these minuscule specks in the body harmless, dangerous, or somewhere in between?
A small study published Wednesday in the New England Journal of Medicine raises more questions than it answers about how these bits—microplastics and the smaller nanoplastics—might affect the heart. The Italian study has weaknesses, but is likely to draw attention to the debate over the problem of plastic pollution. Most plastic waste is never recycled and breaks down into these particles. “The study is intriguing. However, there are really substantial limitatio...
Source: TIME: Health - March 7, 2024 Category: Consumer Health News Authors: CARLA K. JOHNSON/AP Tags: Uncategorized healthscienceclimate Source Type: news
Even Couch Potatoes Reap Health Reward From 10,000 Steps Per Day
WEDNESDAY, March 6, 2024 -- The more steps a person can fit into their day, the lower their risk of early death and heart disease, regardless of how much a couch potato they are otherwise, a new study shows.
People who are sedentary for more than... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 6, 2024 Category: General Medicine Source Type: news
CAC score may predict heart attack, stroke risk
Coronary artery calcium (CAC) scoring with CT could determine whether patients with heart disease symptoms are at low risk of heart attacks or strokes, according to a study published March 5 in Radiology.
The study results could help patients with stable chest pain avoid invasive coronary angiography (ICA), said senior author Marc Dewey, MD, of Charité - Universitätsmedizin Berlin in Germany in a statement released by the RSNA.
"[Our] findings suggest that patients with stable chest pain and a coronary artery calcium score of zero may not require invasive coronary angiography using cardiac catheterization because the r...
Source: AuntMinnie.com Headlines - March 6, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News Subspecialties CT Cardiovascular Radiology Source Type: news
Cleerly CAD Staging System gets FDA nod
Cleerly's coronary artery disease (CAD) Staging System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
The system is a noninvasive imaging-based investigational software device that analyzes features of coronary atherosclerosis, stenosis, and ischemia. It aims to support physicians with risk assessment for patients at risk of major adverse cardiovascular events (MACE), including heart attacks, before they happen.
The Cleerly CAD Staging System was also accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot program, which helps companies make devic...
Source: AuntMinnie.com Headlines - March 5, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Thoracic Imaging Source Type: news
Researchers Are Using AI to Find New Alzheimer ’ s Risk Factors
Brain experts have a pretty good handle on some of the major risk factors that contribute to Alzheimer’s—from a person’s genes to their physical activity levels, how much formal education they’ve received, and how socially engaged they are.
But one promise of AI in medicine is that it can spot less obvious links that humans can’t always see. Could AI help uncover conditions linked to Alzheimer’s that have so far been overlooked?
[time-brightcove not-tgx=”true”]
To find out, Marina Sirota and her team at University of California San Francisco (UCSF) ran a machine-lear...
Source: TIME: Health - March 5, 2024 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news
Mayo Clinic Minute: Why Black Americans are at higher risk of chronic kidney disease
Chronic kidney disease is a condition where your kidneys lose their ability to filter waste and fluid from your blood. This can lead to serious health problems such as heart disease, stroke and kidney failure.The Black community faces a higher risk of chronic kidney disease. This can be due to genetics, higher rates of hypertension and diabetes, and socioeconomic issues such as access to healthcare and structural racism. Dr. Ivan Porter II, a Mayo Clinic nephrologist, says these factors create a… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 5, 2024 Category: Databases & Libraries Source Type: news
Lahey launches heart disease program aimed at South Asian population
South Asians are four time mores likely to develop heart disease than the general population, and are more likely to have and die from Type 2 diabetes. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 4, 2024 Category: Pharmaceuticals Authors: Cassie McGrath Source Type: news
